State Treasurer State of Michigan Buys 300 Shares of Regeneron Pharmaceuticals Inc (REGN)

State Treasurer State of Michigan boosted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 22,544 shares of the biopharmaceutical company’s stock after buying an additional 300 shares during the quarter. State Treasurer State of Michigan’s holdings in Regeneron Pharmaceuticals were worth $9,257,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Smithfield Trust Co. purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Whittier Trust Co. raised its holdings in Regeneron Pharmaceuticals by 195.7% during the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 45 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $29,000. AdvisorNet Financial Inc raised its holdings in Regeneron Pharmaceuticals by 208.0% during the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 52 shares during the period. Finally, Captrust Financial Advisors purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $30,000. Institutional investors own 67.63% of the company’s stock.

In other news, major shareholder Sanofi sold 131,115 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 11.84% of the stock is currently owned by corporate insiders.

Several research firms recently weighed in on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $441.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. Piper Jaffray Companies upped their price objective on Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, January 17th. Finally, Guggenheim downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $466.00 to $425.00 in a research report on Friday, February 22nd. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $404.88.

REGN opened at $304.62 on Wednesday. Regeneron Pharmaceuticals Inc has a 12-month low of $291.10 and a 12-month high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.78 and a current ratio of 4.58. The firm has a market cap of $33.35 billion, a PE ratio of 15.38, a PEG ratio of 1.44 and a beta of 1.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.76 billion. During the same period in the previous year, the company posted $4.67 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 13.3% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.wkrb13.com/2019/05/15/state-treasurer-state-of-michigan-buys-300-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: What is the formula for calculating total return?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.